---
id: 132
title: HIV Antiretroviral Therapy (ART) Initiation and Regimens
category: organisms
subcategory: viruses
tags: [HIV, ART, INSTI, bictegravir, dolutegravir, antiretroviral, viral-load]
difficulty: medium
---

## Question

How is HIV ART initiated? Use the **"Start All HIV+ (Regardless of CD4) with INSTI-Based 3-Drug Regimen"** framework.

## Answer

### **ART Initiation:**

**Universal Recommendation:**
- **Start ART in ALL HIV-positive patients**, regardless of CD4 count
- **Urgent initiation:** Can start same day as diagnosis (if patient ready)
- **Benefits:** Viral suppression, immune reconstitution, prevents transmission

### **Preferred Initial Regimens (2024 DHHS Guidelines):**

**INSTI-Based (Integrase Strand Transfer Inhibitor) - Preferred:**

| Regimen | Components | Dosing | Notes |
|---------|-----------|--------|-------|
| **Bictegravir/TAF/FTC** (Biktarvy) | **Bictegravir 50mg** + tenofovir alafenamide 25mg + emtricitabine 200mg | **1 tablet daily** | **Most preferred**, single-tablet, high barrier to resistance |
| **Dolutegravir/abacavir/lamivudine** (Triumeq) | **Dolutegravir 50mg** + abacavir 600mg + lamivudine 300mg | **1 tablet daily** | **Requires HLA-B*5701 negative** (abacavir hypersensitivity) |
| **Dolutegravir + (TAF or TDF)/FTC** | **Dolutegravir 50mg daily** + FTC/TAF (Descovy) OR FTC/TDF (Truvada) | 2 tablets daily | Alternative if Biktarvy not available |

### **ART Components (3-Drug Regimen):**

**"Backbone" (2 NRTIs):**
- **TAF/FTC (tenofovir alafenamide/emtricitabine)** - preferred (less renal/bone toxicity than TDF)
- **TDF/FTC (tenofovir disoproxil fumarate/emtricitabine)** - alternative (more renal toxicity)
- **Abacavir/lamivudine** - alternative (requires HLA-B*5701 negative)

**"Anchor" Drug (3rd agent):**
- **INSTI (Integrase Inhibitor):** Bictegravir, dolutegravir, raltegravir - **preferred class**
- **NNRTI (Non-Nucleoside RTI):** Efavirenz, rilpivirine - less preferred (more resistance, side effects)
- **PI (Protease Inhibitor):** Darunavir/ritonavir - less preferred (drug interactions, GI side effects)

### **Monitoring:**

**Baseline Labs:**
- **HIV RNA (viral load)**, **CD4 count**
- **Resistance testing** (genotype)
- **HLA-B*5701** (if considering abacavir)
- **Hepatitis B/C serology**
- **CBC, CMP, LFTs, lipid panel**
- **Pregnancy test** (if applicable)

**Follow-Up:**
- **2-4 weeks:** Adherence, side effects, labs (CBC, CMP)
- **4-8 weeks:** **Viral load** (should decline by â‰¥1 log)
- **12-24 weeks:** **Viral load** (goal: **undetectable <50 copies/mL**)
- **Every 3-6 months:** Viral load, CD4 (once stable)

**Goals:**
- **Viral suppression (<50 copies/mL)** by 12-24 weeks
- **Maintain undetectable viral load** (= "U=U" - Undetectable = Untransmittable)

## Key Points

### **Why INSTIs Preferred:**
- **High barrier to resistance** (especially bictegravir, dolutegravir)
- **Rapid viral suppression**
- **Fewer drug interactions** (vs PIs)
- **Well-tolerated** (fewer side effects vs NNRTIs/PIs)
- **Once-daily dosing**

### **Common Side Effects by Class:**

**INSTIs:**
- **Weight gain** (especially bictegravir, dolutegravir)
- **Insomnia** (rare)
- **Dolutegravir:** Neural tube defects (avoid in first trimester pregnancy - now controversial, risk likely low)

**NRTIs:**
- **TAF:** Weight gain, dyslipidemia (less renal/bone toxicity than TDF)
- **TDF:** **Renal toxicity** (Fanconi syndrome), **bone loss**
- **Abacavir:** **Hypersensitivity reaction** (if HLA-B*5701 positive) - can be fatal, never rechallenge

**NNRTIs:**
- **Efavirenz:** **CNS effects** (vivid dreams, dizziness, depression), **teratogenic**
- **Rilpivirine:** Requires food + acid (avoid with PPIs)

**PIs:**
- **GI upset** (diarrhea, nausea)
- **Dyslipidemia**, **insulin resistance**
- **Drug interactions** (ritonavir/cobicistat boosters = CYP3A4 inhibitors)

### **When to Delay ART:**

**Opportunistic Infections:**
- **Cryptococcal meningitis:** Delay ART **2-4 weeks** (reduce IRIS risk)
- **Tuberculosis:** Start ART **2 weeks** after TB therapy (if CD4 <50, start earlier; if CD4 >50, can delay up to 8 weeks)
- **Most other OIs:** Start ART within **2 weeks** of starting OI treatment

### **Resistance Testing:**
- **Obtain genotype** before starting ART (baseline resistance)
- **If virologic failure:** Obtain resistance testing while on failing regimen (or within 4 weeks of stopping)
- **INSTI resistance rare** with bictegravir/dolutegravir (high barrier)

### **Clinical Pearls:**
- **Start ART in ALL HIV+** patients (regardless of CD4)
- **Bictegravir/TAF/FTC (Biktarvy)** = most preferred (1 tablet daily, high barrier to resistance)
- **Goal:** Undetectable viral load (<50 copies/mL) by 12-24 weeks
- **INSTIs preferred** (high barrier to resistance, well-tolerated, once daily)
- **HLA-B*5701 test** before abacavir (hypersensitivity risk)
- **Delay ART 2-4 weeks** after starting cryptococcal meningitis treatment (reduce IRIS)

## Sources

- [DHHS: HIV Guidelines 2024]
- [IAS-USA: Antiretroviral Drugs 2024]

## Media

N/A
